Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas

Phase 2

Completed

• Conditions: Gastric Adenocarcinoma With Peritoneal Carcinomatosis; Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis; Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis
• Interventions: Drug: catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel; Drug: Fluorouracil, leucovorin, oxaliplatin, docetaxel

• Registration Number: NCT01504256
• Lead Sponsor: AIO-Studien-gGmbH

Brief Summary

The purpose of this study is to determine the efficacy of catumaxomab by determination of the rate of macroscopic complete remissions of peritoneal carcinomatosis after treatment with one cycle (four doses) of catumaxomab followed by six cycles of routine neoadjuvant chemotherapy.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-10
• Study First Submitted: 2012-01-03
• Study First Submitted QC: 2012-01-04
• Study First Posted: 2012-01-05
• Primary Completion: 2017-03
• Study Completion: 2017-07
• Status Verified: 2018-01
• Last Update Submitted: 2018-01-19
• Last Update Posted: 2018-01-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

• Histologically confirmed diagnosis of resectable gastric adenocarcinoma or adenocarcinoma of the esophagogastric junction (type II and type III according to Siewerts classification)

• Macroscopic peritoneal carcinomatosis (stage P1-4 according to Gilly et al., appendix 1)

• Patients potentially eligible for gastrectomy after primary systemic (and intraperitoneal) treatment

• Signed and dated informed consent before the start of specific protocol procedures

• Age > 18 years

• ECOG Performance Status of 0 or 1

• Life expectancy of at least 12 weeks

• Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening

  • Hemoglobin > 10.0 g/dl
  • Leukocyte count > 4.000/μl; absolute neutrophil count (ANC) > 2.000/μl
  • Platelet count > = 100.000/µl
  • Total bilirubin < 1,5 times the upper limit of normal
  • ALT and AST < 3 x upper limit of normal
  • Alkaline phosphatase < 5 x ULN
  • Serum creatinine < 1.5 x upper limit of normal and creatinine clearance > 60 ml/min

• The patient is willing and able to comply with the protocol for the duration of the study, including hospital visits for treatment and scheduled follow-up visits and examinations

Exclusion Criteria

• Distant metastasis other than peritoneal seedings

• Prior diagnosis of any malignancy not cured by surgery alone less than 5 years before study entry

• Clinically significant cardiovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) = < 1 year before enrolment

• History of HIV infection or chronic hepatitis B or C

• Active, clinically serious infections (> grade 2 NCI-CTC version 3.0)

• Pre-existing neuropathy > grade 1 (NCI CTCAE), except for loss of tendon reflex

• Patients with seizure disorder requiring medication (such as steroids or antiepileptics)

• History of organ allograft

• Patients undergoing renal dialysis

• Known hypersensitivity to any of the drugs given in the study; known hypersensitivity to murine (rat and/or mouse) proteins

• Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study

• Excluded therapies and medications, previous and concomitant:

  • Prior anti-cancer chemotherapy or immunotherapy.
  • Investigational drug therapy outside of this trial during or within 4 weeks of study entry
  • Major surgery within 4 weeks of starting the study, and patients must have recovered from effects of major surgery

• Pregnant or breast-feeding patients, or planning to become pregnant within 6 months after the end of treatment. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and for 6 months after the end of treatment

• Substance abuse, medical, psychological or social conditions that may interfere with the patient's understanding of the informed consent procedure, participation in the study or evaluation of the study results

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
catumaxomab	catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel	this arm was stopped. the antibody previously used as a study drug is not available at this time. patients will be randomized only into the standard arm \[Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10) and 7 days after the last catumaxomab infusion FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1))
standard therapy	Fluorouracil, leucovorin, oxaliplatin, docetaxel	FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)

Primary Outcome Measures

Name	Time	Method
Rate of macroscopic complete remissions of peritoneal carcinomatosis	Assessment after 14 - 18 weeks after start of treatment	Macroscopic complete response (mCR) rate of the peritoneal lesions, as resulting from the second diagnostic laparoscopy or laparotomy performed after chemotherapy.

Secondary Outcome Measures

Name	Time	Method
Overall survival (OS)	Assessment over minimum 16 months up to 3 years	The duration of overall survival (OS) will be determined by measuring the time interval from randomization to the date of death or last observation (censored).
Immunoreaction against tumor in tissue samples	14 - 18 weeks	blood and tumor tissue from every patient assed at 2time points. the first Laparoscopy (before randomization)and the second Laparoscopy (after chemotherapy)
Frequency, relationship, and severity of AEs	Assessment over minimum 16 months up to 3 years
Detection of disseminated tumor cells via PCR	14 - 18 weeks	blood and tumor tissue from every patient assessed at 2time points. the first Laparoscopy (before randomization) and the second Laparoscopy (after chemotherapy)
Surgical resection rate (R0, R1, R2)	Assessment after 14 - 18 weeks after start of treatment	All tumor evaluation is performed according to RECIST
Disease-free survival (DFS)	Assessment over minimum 16 months up to 3 years	Disease-free survival (DFS) will be defined as the time from surgery, resulting in a R0 finding and macroscopic complete remission of PC, to the time of disease progression or relapse (according to RECIST) or death, or to the date of last assessment without any such event (censored observation). Patients with evidence of disease at surgery are counted as having the event at time = 0.
Progression-free survival (PFS)	Assessment over minimum 16 months up to 3 years	Progression-free survival (PFS) will be defined as the time from randomization to the time of disease progression or relapse (according to RECIST) or death, or to the date of last assessment without any such event (censored observation).

Trial Locations

Locations (1)

Prof. Dr. F. Lordick; 🇩🇪 Leipzig, Germany